Improving North Carolinians’ Health: WellCare & Reinvestment Partners Collaborate

Improving North Carolinians’ Health: WellCare & Reinvestment Partners Collaborate Today, WellCare of North Carolina, a subsidiary of Centene Corporation (NYSE: CNC), unveiled a strategic collaboration with Reinvestment Partners. This partnership aims to leverage the expertise of Reinvestment Partners, a non-profit…

Read MoreImproving North Carolinians’ Health: WellCare & Reinvestment Partners Collaborate

Armis Recognized as Leading Performer in 2024 Best in KLAS Report for Healthcare IoT Security

Armis , the asset intelligence cybersecurity company, today announced it has been named “Top Performer” in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row got. The Best in KLAS report recognizes software…

Read MoreArmis Recognized as Leading Performer in 2024 Best in KLAS Report for Healthcare IoT Security

Revvity Signals Software Introduces Signals Clinical Solution for Expedited Clinical Trial Insights and Informed Data-Driven Decision-Making

Today, Revvity, Inc. (NYSE: RVTY) has unveiled the Signals ClinicalTM solution through its software and informatics division, Revvity Signals. This groundbreaking software-as-a-service (SaaS) platform is designed to revolutionize clinical trial data management, offering comprehensive insights to facilitate informed decision-making and…

Read MoreRevvity Signals Software Introduces Signals Clinical Solution for Expedited Clinical Trial Insights and Informed Data-Driven Decision-Making

Armis Achieves Top Ranking for IoT Security in Healthcare According to the 2024 KLAS Report

Armis, a leading cybersecurity company specializing in asset intelligence, proudly announces its recognition as a top performer in healthcare IoT security for the second consecutive year in the 2024 “Best in KLAS” Software & Services Report. This esteemed accolade underscores…

Read MoreArmis Achieves Top Ranking for IoT Security in Healthcare According to the 2024 KLAS Report

Repare Therapeutics Reacquires Global Rights to Camonsertib

Repare Therapeutics to Regain Global Rights to Camonsertib Following Collaboration Termination with Roche” Repare Therapeutics Inc. (Nasdaq: RPTX), a prominent clinical-stage precision oncology company, has announced its intention to reclaim global development and commercialization rights to camonsertib (RP-3500), a potential…

Read MoreRepare Therapeutics Reacquires Global Rights to Camonsertib

Otsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed at treating agitation associated with dementia due to Alzheimer’s disease…

Read MoreOtsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia

Cencora’s FormularyDecisions Introduces Payer Resource for Cell and Gene Therapy Products

Amidst the growing landscape of cell and gene therapy (CGT) products in clinical development, Cencora’s FormularyDecisions has unveiled a new resource tailored to offer healthcare payers centralized access to information on approved therapies and those in the pipeline. FormularyDecisions, a…

Read MoreCencora’s FormularyDecisions Introduces Payer Resource for Cell and Gene Therapy Products

HCA Healthcare Allocates $100 Million in Grants from the HCA Healthcare Hope Fund to Assist Needy Colleagues

HCA Healthcare, Inc. (NYSE:HCA), a prominent healthcare provider in the United States, has announced that its HCA Healthcare Hope Fund, a 501(c)3 public charity offering emergency aid to colleagues facing significant hardships such as illness, injury, natural disasters, or other…

Read MoreHCA Healthcare Allocates $100 Million in Grants from the HCA Healthcare Hope Fund to Assist Needy Colleagues